US20160357934A1 - Diabetes onset and progression prediction using a computerized model - Google Patents
Diabetes onset and progression prediction using a computerized model Download PDFInfo
- Publication number
- US20160357934A1 US20160357934A1 US14/942,592 US201514942592A US2016357934A1 US 20160357934 A1 US20160357934 A1 US 20160357934A1 US 201514942592 A US201514942592 A US 201514942592A US 2016357934 A1 US2016357934 A1 US 2016357934A1
- Authority
- US
- United States
- Prior art keywords
- data
- diabetes
- patient
- members
- models
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000036541 health Effects 0.000 claims description 47
- 206010061818 Disease progression Diseases 0.000 claims description 9
- 230000005750 disease progression Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 238000013528 artificial neural network Methods 0.000 claims description 3
- 238000003066 decision tree Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000007477 logistic regression Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 230000002250 progressing effect Effects 0.000 claims description 3
- 238000011004 medical lab test Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 17
- 238000012360 testing method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000011218 segmentation Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 206010067671 Disease complication Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013499 data model Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G06F19/3431—
-
- G06F19/3437—
-
- G06F19/345—
-
- G06F19/363—
-
- G06F19/366—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Definitions
- the world health organization estimates that the incidence of diabetes in the United States will almost double during the time period of 2000-2030.
- the Centers for Disease Control and Prevention estimated that in 2010 there were 26 million people in the United States that had diabetes with greater than 25 percent of that number being undiagnosed.
- the National Diabetes Information Clearinghouse has estimated that diabetes costs in the United States are $132 billion a year.
- gestational diabetes is a complication of pregnancy and not suffered by the population at large.
- Type I diabetes is genetic in origin, non-preventable, but inevitably accounts for only 5% of diabetes.
- the more prevalent type of diabetes is type II.
- Type II diabetes is preventable or at least controllable through the implementation of a healthy lifestyle and medication. Therefore, approximately 95% of diabetes instances may be prevented or controlled by lifestyle changes and medication.
- diabetes can progress in severity to the point that a buildup of glucose in the patient's bloodstream may result in such complications as cardiovascular disease, vision loss, kidney failure, and even amputation of limbs.
- a patient must be aware of his or her diabetic condition.
- prediction may be extremely beneficial to help care providers identify those persons who may have a high risk of developing diabetes. Further, identification of those who currently have diabetes who may be at risk of worsening symptoms is key to help those patients suffering from diabetes effectively manage their condition to avoid or minimize disease progression and the resulting negative health impacts.
- Caregivers and insurance providers also may have an interest in detecting a patient's diabetic or pre-diabetic condition.
- caregivers and insurance providers may have an interest in predicting the likelihood that a patient currently exhibiting symptoms of the disease will progress to worsening levels of diabetes symptoms.
- the cost to treat a patient's diabetic condition increases dramatically as that patient progresses from less severe to more severe diabetes symptoms. Therefore, a prediction of the likelihood that a segment of population may be at greater risk of developing or suffering a progression of an existing disease condition may be used by caregivers and insurance providers to identify patients with higher levels of risk and proactively initiate monitoring and the provision of appropriate care.
- More aggressive monitoring may help to detect the onset of diabetes while increased levels of care may prevent that onset.
- increased levels of care may prevent the disease from progressing to more severe stages.
- monitoring that results in earlier detection or proactive care may have the additional benefit of reducing the cost of providing care or health insurance to such a person.
- What is needed is a computerized system and method for identifying segments of a non-diabetic population that are most likely to develop diabetes over an identified period of time. Also needed is a computerized system and method for identifying those segments of a diabetic population that are likely to experience a progression in the severity of their diabetes and related complications.
- Such a system and method may use a severity index to both identify the severity of a diabetic condition and predict the likelihood of disease progression.
- input data for use by a predictive model may be collected from a population group.
- An example of such a group may be persons who are provided coverage by a health insurance provider.
- input data may comprise insurance claims, lab test results, participation in health improvement programs, the output of medical and insurance claim data analysis systems, Medicare data, survey data, population demographics and other population characterizing data.
- This data may be processed to optimize and transform the various data components into analyzable population data. After optimization, data may be further processed to segment the data into population segments with common data characteristics and detail levels.
- Predictive models may then be applied to each segment to predict diabetes occurrence and progression risk for population members who are suffering from diabetes at the time of analysis. Once such predications have been performed, actions such as testing, treatment, or counseling may be implemented to reduce the predicted occurrences and slow the progression of the disease in those population members which exhibit symptoms.
- FIG. 1 is an illustration of modeling process in which data is input and used to develop predictive models
- FIG. 2 is a graphic illustration of a system for analyzing population data to generate a predicted risk of disease or disease progression when the disease exists in a population member;
- FIG. 3 is an illustration of the output of the modeling process showing a comparison between prediction of the onset of diabetes for members of a population to which risk scores have been assigned and those population members which were randomly selected;
- FIG. 4 is a chart of the member data characteristics that were top predictors of the incidence of diabetes in those members who were not diabetic at the time the analysis was performed;
- FIG. 5 is a graph showing the percentage of population members with predicted high risk that develop diabetes over a period of time
- FIG. 6 is a chart of model performance when calculating the predicted progression of diabetes complications among members of a diabetic population.
- FIG. 7 is a chart of the top predictors of increase in the progression of diabetes complication among members of a diabetic population group.
- a model to predict the likelihood of the onset of diabetes is integrated into a software application that may be used by a health insurance provider to predict such a likelihood within a covered patient-member population.
- a model to predict the onset of diabetes may retrieve and analyze data from a population that may be susceptible to the development of diabetes.
- population health data There are many sources of population health data; however, in an embodiment for use by health insurance providers, one source of such data particular to health insurance providers may be claims and health records for the patient-members who form the population.
- an insurance company may have a particular interest in the subject of this invention to assist in the provision of care to individuals who are members of a health plan.
- the invention should not be interpreted as being limited to health plan members, the term “members” will be used to describe a population for which data is analyzed to predict the onset or progression of diabetes in embodiments of the invention. In other embodiments, those individuals whose medical information and characteristics are being analyzed may be patients of a care provider and thus may be referred to as patients. Other embodiments of the invention may be used to predict the progression of an existing diabetic disease. Such embodiments may utilize data similar to embodiments which predict the onset of diabetes. These embodiments may also be integrated into a software application used to analyze the input data and generate such predictions. As noted above, such embodiments may be useful for health plan providers, healthcare providers, and other organizations concerned with the health of population members, and as such, interpretation of this description should not be limited to applications utilized by health plan providers only.
- input data 102 may be comprised from a plurality of sources. These sources may include both data source from public repositories such as Medicaid/Medicare data (CMS Data) and information derived from consumers of medical services. Other sources of data may be derived from member data maintained by health plan providers. Examples of such information may be member health surveys, membership demographics, membership in certain healthcare groups, and participation in various health programs, summarized lab test results, claims for medical care, claims for pharmacy services, and consumer data.
- CMS Data Medicaid/Medicare data
- Other sources of data may be derived from member data maintained by health plan providers. Examples of such information may be member health surveys, membership demographics, membership in certain healthcare groups, and participation in various health programs, summarized lab test results, claims for medical care, claims for pharmacy services, and consumer data.
- health surveys which may be used in embodiments of the invention is the Medicare Domain Assessment Tool, in which questions about the patient's health/frailty/mental status are asked.
- the past coverage of the members may be obtained, which may allow an embodiment of the invention to normalize the past healthcare resources utilizations.
- a health care provider may provide various disease management programs to help members manage their clinical conditions. The participation of the programs may also provide valuable information about patient's health status and future behavior.
- Consumer data may provide information about the socio-economic status of a member, such as estimated household income, education, and life-style, which may also play a significant role in predicting the disease progression.
- Another source of data may be comprised of calculated member data such as health risks alerts generated by a medical analytics system.
- Input data may also include data from medical records, data from health monitoring devices, social media data, and other sources of data which provide patent behavior or characteristics information.
- a data feature extraction process 104 may be implemented to identify data variables from the various sources. Extracted data may be optimized through the use of summarization, standardization and filtration processes.
- the extracted features may describe the patient's demographic profile, clinical profile, behavior profile, medication profile and disease progression profiles.
- Example member demographic profile features may include age, gender, race and socio-economic status; example clinical profiles include chronic conditions, mental health conditions, hospitalizations, medication etc; example behavior profiles include health program participations; example medication profile includes adherence to various medications, such as diabetes, heart failure, coronary artery disease, etc; example progression profiles include characteristics that describe the disease progression history.
- data may be analyzed to detect interactions between the various data sources.
- An example of such analysis may be processing Medicaid and Medicare record information to identify population risks related to a particular characteristic of a segment of the public. That characteristic may then be used to identify segments of the member data from a health plan provider to optimize the presentation of member data with regard to the identified characteristic.
- the members identified by the extracted and transformed data may be segmented based on characteristic homogeneity and data availability 106 . Such segmentation may be performed based on information comprised from within the member data. Segmentation may also be performed based on a variety of hypotheses that are applied to member data. Example hypotheses may include, but are not limited to, new members, continuous or existing members, line of business, and other such factors that differentiate members of the population. These examples may be used alone or in combination.
- the data may have a plurality of models applied to capture the relationship between a member's data characteristics and potential future health conditions for that member 108 .
- the results of this plurality of models as well as the methods used to segment the population may be subject to various forms of validation testing.
- Examples of such testing may be the application of models to validate data in order to identify models exhibiting the desired level of performance and then an application of the model to a larger and independent set of test data to verify the results match those of the smaller validation population.
- This testing may serve to identify the most accurate methods of segmentation and applied models with regard to the predictions derived from their application to sample population data. Once these models are identified, they may be applied to new data in order to perform the prediction and identification desired by the health care or health plan provider which is responsible for the member or patient population.
- data models may be used to predict the progression between various stages of diabetes for those members who have already begun to exhibit disease symptoms.
- input data 102 may be comprised from a plurality of different sources. These sources may include both data source from public repositories and from non-public sources such as such as member data maintained by a health plan provider. Another source of data may be comprised of calculated data as was described above.
- FIG. 2 shows an embodiment of the invention that illustrates the use of different models for different population groups identified during a segmentation stage 106 .
- input data may be gathered and divided into population segments grouped by profile 204 . Because these profiles may result in population segments with different risk characteristics, accurate scoring or prediction of member risk may require different models for each population segment.
- the models may be neural network, logistic regression, decision tree, or similar modeling methods or a combination of several models, i.e. ensemble models. This result is illustrated at 206 .
- an embodiment of the invention may apply a plurality of models to each population segment. Holdout test data may be used to verify each model and select that model with the most accurate prediction of disease.
- an embodiment of the invention may apply those models to segmented population data as illustrated in FIG. 2 .
- a list of members 208 may be produced that is scored according to the risk detected by the plurality of models.
- the scored member list 208 may be used to initiate phone communications 210 to help the member better manage the condition of a member contained in the list.
- the list may also be used to contact the member for the provision of information to encourage and assist self-management activities by the member.
- a scored list may also serve to trigger a visit by a health care provider (here illustrated as a nurse) to a patient 214 .
- the output of a diabetes incidence prediction model as compared to randomly selected population members is illustrated in FIG. 3 .
- the incidence of the development of diabetes in randomly selected members from a health plan is illustrated at 302 .
- the incidence of diabetes most likely corresponds linearly based on the percentage of members. For example, the top 10% of members corresponds to 10% of the overall development of diabetes, the top 20% of members corresponds to 20% of the overall development of diabetes and so-on as the percentage of members approaches 100%.
- randomly selecting members is not useful for the prediction of the occurrence of diabetes beyond the percentage of the population corresponding to a percentage of the overall number of the population that will develop diabetes.
- the result of the predictive model being applied to the population is illustrated at 304 .
- the scoring applied to the analyzed member data is significantly more likely to predict the occurrence of diabetes in the analyzed population than random selection.
- the top 10% of members ranked by the modeled prediction score yielded approximately 33% of those members that developed diabetes.
- the top 20% of those members ranked according the predictive model yielded approximately 49%, and so-on as the percentage of ranked members is increased.
- greater than 60% of those members that will develop diabetes during a predetermined time are identified in the top 30% of the rankings applied to those members analyzed.
- the model was twice as likely to identify a member at risk of developing diabetes symptoms as would be selecting members at random.
- the top predictors used in the model of FIG. 3 are listed in the chart of FIG. 4 . For instance, among risk factors identified in the member data, obesity and smoking were top predictors of the development of diabetes.
- models may be applied to identify those members at most risk of developing diabetes as time elapses.
- line 502 represents those members ranked in the top 5% by the predictive model.
- Line 504 represents the top 10%
- line 506 represents the top 20%
- line 508 represents the entirety of those members who develop diabetes during the illustrated time period. Moving from left to right along the graph represents the number of days that elapse before an identified member develops diabetes symptoms. Among all member segments, there is a median (50% of members developing diabetes) of at least 60-90 days of time between scoring and developing diabetes, providing time for identified members receiving proactive intervention.
- a risk score may be generated that reflects a member's risk of progressing to a higher incidence of diabetes disease complications. Such a risk score may be useful to a health plan or medical care provider seeking to initiate contact with members of the insured population at risk for developing a higher level of disease complications. As noted above, the cost of treating a diabetes patient's disease symptoms increases as the severity of those conditions increases. Thus, identification may allow a care or health plan provider to proactively make contact with a member to encourage that member to take actions to mitigate the risk of such progression.
- a system and method may utilize inputs such as Medicaid/Medicare data (CMS Data) and information derived from consumers of medical services.
- CMS Data Medicaid/Medicare data
- Other sources of data may be derived from member data maintained by health plan providers. Examples of such information may be member health surveys, membership demographics, membership in certain healthcare groups, and participation in various health programs.
- Another source of data may be comprised of calculated member data such as alerts of identified health risks generated by medical analytics systems, lab test results, claims for medical care, and claims for pharmacy services.
- the model may also include data from medical record, data from health monitoring devices, social media data, etc.
- the above noted inputs may be combined with a disease severity index used to rate a patient's symptoms relative to a general population.
- a disease severity index used to rate a patient's symptoms relative to a general population.
- One such severity index is the Diabetes Complications Severity Index (DCSI) which is a standardized methodology used in the healthcare industry to quantify the extent to which body systems in addition to those directly related to the diabetic condition are impacted by the progression of diabetes in a patient.
- DCSI provides an index score for a patient based upon the presence of cardiovascular, cerebrovascular, metabolic, nephropathy, neuropathy, peripheral vascular disease and retinopathy conditions in the patient.
- an embodiment of the invention may analyze a patient's medical record data to detect the presence of specific sets of International Classification of Diseases (ICD9) codes. Should codes be detected that indicate one or more of these conditions are present, a point value may be assigned to the identified condition.
- each condition is assigned a value of one or two points, depending on the condition severity, as described by the ICD9 codes, with the exception of Neuropathy, which is assigned a point value of one. These point values are summed, resulting in a DCSI score ranging from zero to thirteen. A score of zero indicates an absence of any complication condition, and a score of 13 indicates that a patient has indications corresponding to each of the seven identified conditions.
- FIG. 6 illustrates the performance of two models, based on Medicare patient health data, used to determine the risk of complication progression over a period of time.
- three categories were identified, a low severity index range category with DCSI scores ranging from 0-3, a medium severity range with DCSI scores ranging from 4-7, and a high severity category which includes the range of 8-13.
- a model based on Diabetes Complication Severity Index 602 returns a 66% 604 rate of detections of severity index progression from low/medium to high and 30% 606 from a severity index of low to medium/high for those members in the top 10% of prediction rankings 608 .
- the top 10% also includes 23% of those member's whose DCSI score increases by two or more points 610 .
- those members in the top 30% of prediction rankings 612 comprise 91% of the members whose DCSI score progresses from low/medium to high 614 and 65% of those members whose DCSI score progresses from low to medium/high 616 .
- the top 30% of the prediction rankings also captured 50% of those members whose DCSI score increased by two or more points 618 .
- Receiver operating characteristic (ROC) scores are also shown for each level of progression. These scores indicate the performance of a model taking into account both correct indications as well as those that are incorrectly positive or negative indications.
- FIG. 6 also illustrates the results of a second model based on binary DCSI groupings 620 , in which the prediction target is whether the member has progressed to a more severe stage. As is shown, the top 30% of the prediction rankings produce slightly improved capture rates of those members who progress from low/medium to high DCSI scores 622 and those who progress from low to medium/high DCSI scores 624 .
- the prediction target is whether the member has progressed to a more severe stage.
- top predictors may be those listed in FIG. 7 . As is shown, these predictors may be separated into categories such as clinical predictors 702 , risk scores 704 related to Medicare Advantage scores 706 and prescription risk 708 . Predictors may also comprise indications of disease progression 710 such as the change in DCSI score over time 712 and the number of medical claims over a period of time 714 . In addition to clinical, risk and progression characteristics, the demographic characteristics 716 of a member or patient may also be used to predict the progression of diabetes.
- any embodiment of the present invention may include any of the optional or preferred features of the other embodiments of the present invention.
- the exemplary embodiments herein disclosed are not intended to be exhaustive or to unnecessarily limit the scope of the invention.
- the exemplary embodiments were chosen and described in order to explain the principles of the present invention so that others skilled in the art may practice the invention. Having shown and described exemplary embodiments of the present invention, those skilled in the art will realize that many variations and modifications may be made to the described invention. Many of those variations and modifications will provide the same result and fall within the spirit of the claimed invention. It is the intention, therefore, to limit the invention only as indicated by the scope of the claims.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
- This application claims priority to US Provisional Patent Application Ser. No. 62/079,962, filed Nov. 14, 2014, the contents of which is incorporated herein by reference.
- BACKGROUND AND SUMMARY OF THE INVENTION
- The world health organization estimates that the incidence of diabetes in the United States will almost double during the time period of 2000-2030. The Centers for Disease Control and Prevention estimated that in 2010 there were 26 million people in the United States that had diabetes with greater than 25 percent of that number being undiagnosed. The National Diabetes Information Clearinghouse has estimated that diabetes costs in the United States are $132 billion a year.
- As noted above, it has been estimated that greater than 25 percent of those with diabetes in the United States are unaware of their condition. Patients who are unaware of their diabetes are at greater risk for a worsening of the disease or other health conditions and complications that arise as the result of the failure to treat their undetected diabetes. As with many other types of diseases, the symptoms of diabetes may vary along a continuum from minor to severe. In addition to greater health risks as the result of failure to treat their diabetic condition, a worsening of a patient's condition may markedly increase their cost of care. Treatment cost data indicates that a patient with high severity diabetes may have costs that are eight times as much as a patient with low severity symptoms. There are three types of diabetes: type I; type II; and gestational diabetes. As its name suggests, gestational diabetes is a complication of pregnancy and not suffered by the population at large. Type I diabetes is genetic in origin, non-preventable, but fortunately accounts for only 5% of diabetes. The more prevalent type of diabetes is type II. Type II diabetes is preventable or at least controllable through the implementation of a healthy lifestyle and medication. Therefore, approximately 95% of diabetes instances may be prevented or controlled by lifestyle changes and medication. Additionally, without treatment, diabetes can progress in severity to the point that a buildup of glucose in the patient's bloodstream may result in such complications as cardiovascular disease, vision loss, kidney failure, and even amputation of limbs. However, to treat or prevent progression of the disease, a patient must be aware of his or her diabetic condition. Therefore, prediction may be extremely beneficial to help care providers identify those persons who may have a high risk of developing diabetes. Further, identification of those who currently have diabetes who may be at risk of worsening symptoms is key to help those patients suffering from diabetes effectively manage their condition to avoid or minimize disease progression and the resulting negative health impacts.
- Caregivers and insurance providers also may have an interest in detecting a patient's diabetic or pre-diabetic condition. In addition to detection, caregivers and insurance providers may have an interest in predicting the likelihood that a patient currently exhibiting symptoms of the disease will progress to worsening levels of diabetes symptoms. As noted above, the cost to treat a patient's diabetic condition increases dramatically as that patient progresses from less severe to more severe diabetes symptoms. Therefore, a prediction of the likelihood that a segment of population may be at greater risk of developing or suffering a progression of an existing disease condition may be used by caregivers and insurance providers to identify patients with higher levels of risk and proactively initiate monitoring and the provision of appropriate care.
- More aggressive monitoring may help to detect the onset of diabetes while increased levels of care may prevent that onset. For persons who already have diabetes symptoms, increased levels of care may prevent the disease from progressing to more severe stages. In either case, in addition to helping persons avoid diabetes entirely or minimize the progression of symptoms, monitoring that results in earlier detection or proactive care may have the additional benefit of reducing the cost of providing care or health insurance to such a person.
- What is needed is a computerized system and method for identifying segments of a non-diabetic population that are most likely to develop diabetes over an identified period of time. Also needed is a computerized system and method for identifying those segments of a diabetic population that are likely to experience a progression in the severity of their diabetes and related complications.
- Such a system and method may use a severity index to both identify the severity of a diabetic condition and predict the likelihood of disease progression. In embodiments of the invention, input data for use by a predictive model may be collected from a population group. An example of such a group may be persons who are provided coverage by a health insurance provider. In an embodiment of the invention, input data may comprise insurance claims, lab test results, participation in health improvement programs, the output of medical and insurance claim data analysis systems, Medicare data, survey data, population demographics and other population characterizing data. This data may be processed to optimize and transform the various data components into analyzable population data. After optimization, data may be further processed to segment the data into population segments with common data characteristics and detail levels. Predictive models may then be applied to each segment to predict diabetes occurrence and progression risk for population members who are suffering from diabetes at the time of analysis. Once such predications have been performed, actions such as testing, treatment, or counseling may be implemented to reduce the predicted occurrences and slow the progression of the disease in those population members which exhibit symptoms.
- In addition to the features mentioned above, other aspects of the present invention will be readily apparent from the following descriptions of the drawings and exemplary embodiments, wherein like reference numerals across the several views refer to identical or equivalent features, and wherein:
-
FIG. 1 is an illustration of modeling process in which data is input and used to develop predictive models; -
FIG. 2 is a graphic illustration of a system for analyzing population data to generate a predicted risk of disease or disease progression when the disease exists in a population member; -
FIG. 3 is an illustration of the output of the modeling process showing a comparison between prediction of the onset of diabetes for members of a population to which risk scores have been assigned and those population members which were randomly selected; -
FIG. 4 is a chart of the member data characteristics that were top predictors of the incidence of diabetes in those members who were not diabetic at the time the analysis was performed; -
FIG. 5 is a graph showing the percentage of population members with predicted high risk that develop diabetes over a period of time; -
FIG. 6 is a chart of model performance when calculating the predicted progression of diabetes complications among members of a diabetic population; and -
FIG. 7 is a chart of the top predictors of increase in the progression of diabetes complication among members of a diabetic population group. - Various embodiments of the present invention will now be described in detail with reference to the accompanying drawings. In the following description, specific details such as detailed configuration and components are merely provided to assist the overall understanding of these embodiments of the present invention. Therefore, it should be apparent to those skilled in the art that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present invention. In addition, descriptions of well-known functions and constructions are omitted for clarity and conciseness.
- In an example embodiment, a model to predict the likelihood of the onset of diabetes is integrated into a software application that may be used by a health insurance provider to predict such a likelihood within a covered patient-member population. As described herein, a model to predict the onset of diabetes may retrieve and analyze data from a population that may be susceptible to the development of diabetes. There are many sources of population health data; however, in an embodiment for use by health insurance providers, one source of such data particular to health insurance providers may be claims and health records for the patient-members who form the population. As noted above, an insurance company may have a particular interest in the subject of this invention to assist in the provision of care to individuals who are members of a health plan. In addition to providing improved levels of care to such individuals, early detection and management may reduce the cost of care and thus the cost of health coverage for the member, improving the financial performance of an insurance provider. While the invention should not be interpreted as being limited to health plan members, the term “members” will be used to describe a population for which data is analyzed to predict the onset or progression of diabetes in embodiments of the invention. In other embodiments, those individuals whose medical information and characteristics are being analyzed may be patients of a care provider and thus may be referred to as patients. Other embodiments of the invention may be used to predict the progression of an existing diabetic disease. Such embodiments may utilize data similar to embodiments which predict the onset of diabetes. These embodiments may also be integrated into a software application used to analyze the input data and generate such predictions. As noted above, such embodiments may be useful for health plan providers, healthcare providers, and other organizations concerned with the health of population members, and as such, interpretation of this description should not be limited to applications utilized by health plan providers only.
- Referring to
FIG. 1 ,input data 102 may be comprised from a plurality of sources. These sources may include both data source from public repositories such as Medicaid/Medicare data (CMS Data) and information derived from consumers of medical services. Other sources of data may be derived from member data maintained by health plan providers. Examples of such information may be member health surveys, membership demographics, membership in certain healthcare groups, and participation in various health programs, summarized lab test results, claims for medical care, claims for pharmacy services, and consumer data. One example of health surveys which may be used in embodiments of the invention is the Medicare Domain Assessment Tool, in which questions about the patient's health/frailty/mental status are asked. For the membership information, the past coverage of the members may be obtained, which may allow an embodiment of the invention to normalize the past healthcare resources utilizations. A health care provider may provide various disease management programs to help members manage their clinical conditions. The participation of the programs may also provide valuable information about patient's health status and future behavior. Consumer data may provide information about the socio-economic status of a member, such as estimated household income, education, and life-style, which may also play a significant role in predicting the disease progression. Another source of data may be comprised of calculated member data such as health risks alerts generated by a medical analytics system. Input data may also include data from medical records, data from health monitoring devices, social media data, and other sources of data which provide patent behavior or characteristics information. - Because of the diversity of sources from which
input data 102 may be comprised, a datafeature extraction process 104 may be implemented to identify data variables from the various sources. Extracted data may be optimized through the use of summarization, standardization and filtration processes. The extracted features may describe the patient's demographic profile, clinical profile, behavior profile, medication profile and disease progression profiles. Example member demographic profile features may include age, gender, race and socio-economic status; example clinical profiles include chronic conditions, mental health conditions, hospitalizations, medication etc; example behavior profiles include health program participations; example medication profile includes adherence to various medications, such as diabetes, heart failure, coronary artery disease, etc; example progression profiles include characteristics that describe the disease progression history. In addition to standardization and filtration, data may be analyzed to detect interactions between the various data sources. An example of such analysis may be processing Medicaid and Medicare record information to identify population risks related to a particular characteristic of a segment of the public. That characteristic may then be used to identify segments of the member data from a health plan provider to optimize the presentation of member data with regard to the identified characteristic. - When data has been processed to extract and transform key data features into standardized data formats, the members identified by the extracted and transformed data may be segmented based on characteristic homogeneity and
data availability 106. Such segmentation may be performed based on information comprised from within the member data. Segmentation may also be performed based on a variety of hypotheses that are applied to member data. Example hypotheses may include, but are not limited to, new members, continuous or existing members, line of business, and other such factors that differentiate members of the population. These examples may be used alone or in combination. Once segmented, the data may have a plurality of models applied to capture the relationship between a member's data characteristics and potential future health conditions for thatmember 108. - The results of this plurality of models as well as the methods used to segment the population may be subject to various forms of validation testing. Examples of such testing may be the application of models to validate data in order to identify models exhibiting the desired level of performance and then an application of the model to a larger and independent set of test data to verify the results match those of the smaller validation population. This testing may serve to identify the most accurate methods of segmentation and applied models with regard to the predictions derived from their application to sample population data. Once these models are identified, they may be applied to new data in order to perform the prediction and identification desired by the health care or health plan provider which is responsible for the member or patient population.
- In another embodiment of the invention, data models may be used to predict the progression between various stages of diabetes for those members who have already begun to exhibit disease symptoms. As with the previously described embodiment,
input data 102 may be comprised from a plurality of different sources. These sources may include both data source from public repositories and from non-public sources such as such as member data maintained by a health plan provider. Another source of data may be comprised of calculated data as was described above. -
FIG. 2 shows an embodiment of the invention that illustrates the use of different models for different population groups identified during asegmentation stage 106. As is illustrated at 202, input data may be gathered and divided into population segments grouped byprofile 204. Because these profiles may result in population segments with different risk characteristics, accurate scoring or prediction of member risk may require different models for each population segment. The models may be neural network, logistic regression, decision tree, or similar modeling methods or a combination of several models, i.e. ensemble models. This result is illustrated at 206. To determine the best models for each segment, an embodiment of the invention may apply a plurality of models to each population segment. Holdout test data may be used to verify each model and select that model with the most accurate prediction of disease. Once the best models have been determined for the population segments, an embodiment of the invention may apply those models to segmented population data as illustrated inFIG. 2 . Once these models are applied, a list ofmembers 208 may be produced that is scored according to the risk detected by the plurality of models. As is illustrated, the scoredmember list 208 may be used to initiatephone communications 210 to help the member better manage the condition of a member contained in the list. The list may also be used to contact the member for the provision of information to encourage and assist self-management activities by the member. A scored list may also serve to trigger a visit by a health care provider (here illustrated as a nurse) to apatient 214. - The output of a diabetes incidence prediction model as compared to randomly selected population members is illustrated in
FIG. 3 . As is shown, the incidence of the development of diabetes in randomly selected members from a health plan is illustrated at 302. In a randomly selected sample, the incidence of diabetes most likely corresponds linearly based on the percentage of members. For example, the top 10% of members corresponds to 10% of the overall development of diabetes, the top 20% of members corresponds to 20% of the overall development of diabetes and so-on as the percentage of members approaches 100%. One skilled in the art will realized that randomly selecting members is not useful for the prediction of the occurrence of diabetes beyond the percentage of the population corresponding to a percentage of the overall number of the population that will develop diabetes. However, the result of the predictive model being applied to the population is illustrated at 304. - As is shown, the scoring applied to the analyzed member data is significantly more likely to predict the occurrence of diabetes in the analyzed population than random selection. For example, in the results of the predictive model, the top 10% of members ranked by the modeled prediction score yielded approximately 33% of those members that developed diabetes. The top 20% of those members ranked according the predictive model yielded approximately 49%, and so-on as the percentage of ranked members is increased. As shown, greater than 60% of those members that will develop diabetes during a predetermined time are identified in the top 30% of the rankings applied to those members analyzed. In other words, the model was twice as likely to identify a member at risk of developing diabetes symptoms as would be selecting members at random. The top predictors used in the model of
FIG. 3 are listed in the chart ofFIG. 4 . For instance, among risk factors identified in the member data, obesity and smoking were top predictors of the development of diabetes. - In another embodiment of the invention, models may be applied to identify those members at most risk of developing diabetes as time elapses. For instance, referring to
FIG. 5 ,line 502 represents those members ranked in the top 5% by the predictive model.Line 504 represents the top 10%,line 506 represents the top 20%, andline 508 represents the entirety of those members who develop diabetes during the illustrated time period. Moving from left to right along the graph represents the number of days that elapse before an identified member develops diabetes symptoms. Among all member segments, there is a median (50% of members developing diabetes) of at least 60-90 days of time between scoring and developing diabetes, providing time for identified members receiving proactive intervention. - In embodiments of the invention that apply models to predict the progression of a patient's diabetes symptoms, a risk score may be generated that reflects a member's risk of progressing to a higher incidence of diabetes disease complications. Such a risk score may be useful to a health plan or medical care provider seeking to initiate contact with members of the insured population at risk for developing a higher level of disease complications. As noted above, the cost of treating a diabetes patient's disease symptoms increases as the severity of those conditions increases. Thus, identification may allow a care or health plan provider to proactively make contact with a member to encourage that member to take actions to mitigate the risk of such progression. When identifying members at risk of developing increased levels of diabetes symptoms, a system and method may utilize inputs such as Medicaid/Medicare data (CMS Data) and information derived from consumers of medical services. Other sources of data may be derived from member data maintained by health plan providers. Examples of such information may be member health surveys, membership demographics, membership in certain healthcare groups, and participation in various health programs. Another source of data may be comprised of calculated member data such as alerts of identified health risks generated by medical analytics systems, lab test results, claims for medical care, and claims for pharmacy services. The model may also include data from medical record, data from health monitoring devices, social media data, etc.
- In embodiments of the invention which predict the progression of a member's diabetes symptoms, the above noted inputs may be combined with a disease severity index used to rate a patient's symptoms relative to a general population. One such severity index is the Diabetes Complications Severity Index (DCSI) which is a standardized methodology used in the healthcare industry to quantify the extent to which body systems in addition to those directly related to the diabetic condition are impacted by the progression of diabetes in a patient. DCSI provides an index score for a patient based upon the presence of cardiovascular, cerebrovascular, metabolic, nephropathy, neuropathy, peripheral vascular disease and retinopathy conditions in the patient. In order to identify the presence of these conditions in a patient, an embodiment of the invention may analyze a patient's medical record data to detect the presence of specific sets of International Classification of Diseases (ICD9) codes. Should codes be detected that indicate one or more of these conditions are present, a point value may be assigned to the identified condition. In an exemplary embodiment employing the DCSI, each condition is assigned a value of one or two points, depending on the condition severity, as described by the ICD9 codes, with the exception of Neuropathy, which is assigned a point value of one. These point values are summed, resulting in a DCSI score ranging from zero to thirteen. A score of zero indicates an absence of any complication condition, and a score of 13 indicates that a patient has indications corresponding to each of the seven identified conditions.
-
FIG. 6 illustrates the performance of two models, based on Medicare patient health data, used to determine the risk of complication progression over a period of time. In order to illustrate the grouping patients using their DCSI scores, three categories were identified, a low severity index range category with DCSI scores ranging from 0-3, a medium severity range with DCSI scores ranging from 4-7, and a high severity category which includes the range of 8-13. In the illustrated figure, a model based on DiabetesComplication Severity Index 602 returns a 66% 604 rate of detections of severity index progression from low/medium to high and 30% 606 from a severity index of low to medium/high for those members in the top 10% ofprediction rankings 608. The top 10% also includes 23% of those member's whose DCSI score increases by two ormore points 610. Using the same model, those members in the top 30% ofprediction rankings 612 comprise 91% of the members whose DCSI score progresses from low/medium to high 614 and 65% of those members whose DCSI score progresses from low to medium/high 616. The top 30% of the prediction rankings also captured 50% of those members whose DCSI score increased by two ormore points 618. Receiver operating characteristic (ROC) scores are also shown for each level of progression. These scores indicate the performance of a model taking into account both correct indications as well as those that are incorrectly positive or negative indications. As is illustrated in this example, such a model may permit an entity such as a health plan provider or healthcare provider executing the illustrated model to identify a large percentage of those members or patients at risk of progression to a higher level of diabetes severity. Those members may then be contacted to offer forms of intervention or treatment that may reduce the likelihood of progression.FIG. 6 also illustrates the results of a second model based onbinary DCSI groupings 620, in which the prediction target is whether the member has progressed to a more severe stage. As is shown, the top 30% of the prediction rankings produce slightly improved capture rates of those members who progress from low/medium tohigh DCSI scores 622 and those who progress from low to medium/high DCSI scores 624. In the example models illustrated inFIG. 6 , top predictors may be those listed inFIG. 7 . As is shown, these predictors may be separated into categories such asclinical predictors 702, risk scores 704 related to Medicare Advantage scores 706 andprescription risk 708. Predictors may also comprise indications ofdisease progression 710 such as the change in DCSI score overtime 712 and the number of medical claims over a period oftime 714. In addition to clinical, risk and progression characteristics, thedemographic characteristics 716 of a member or patient may also be used to predict the progression of diabetes. - Any embodiment of the present invention may include any of the optional or preferred features of the other embodiments of the present invention. The exemplary embodiments herein disclosed are not intended to be exhaustive or to unnecessarily limit the scope of the invention. The exemplary embodiments were chosen and described in order to explain the principles of the present invention so that others skilled in the art may practice the invention. Having shown and described exemplary embodiments of the present invention, those skilled in the art will realize that many variations and modifications may be made to the described invention. Many of those variations and modifications will provide the same result and fall within the spirit of the claimed invention. It is the intention, therefore, to limit the invention only as indicated by the scope of the claims.
Claims (15)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/942,592 US20160357934A1 (en) | 2014-11-14 | 2015-11-16 | Diabetes onset and progression prediction using a computerized model |
| US17/962,732 US20230035564A1 (en) | 2014-11-14 | 2022-10-10 | Diabetes onset and progression prediction using a computerized model |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079962P | 2014-11-14 | 2014-11-14 | |
| US14/942,592 US20160357934A1 (en) | 2014-11-14 | 2015-11-16 | Diabetes onset and progression prediction using a computerized model |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/962,732 Continuation US20230035564A1 (en) | 2014-11-14 | 2022-10-10 | Diabetes onset and progression prediction using a computerized model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20160357934A1 true US20160357934A1 (en) | 2016-12-08 |
Family
ID=57451478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/942,592 Abandoned US20160357934A1 (en) | 2014-11-14 | 2015-11-16 | Diabetes onset and progression prediction using a computerized model |
| US17/962,732 Pending US20230035564A1 (en) | 2014-11-14 | 2022-10-10 | Diabetes onset and progression prediction using a computerized model |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/962,732 Pending US20230035564A1 (en) | 2014-11-14 | 2022-10-10 | Diabetes onset and progression prediction using a computerized model |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20160357934A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190259104A1 (en) * | 2018-02-16 | 2019-08-22 | Munich Reinsurance America, Inc. | Computer-implemented methods, computer-readable media, and systems for identifying causes of loss |
| US20190357853A1 (en) * | 2018-05-24 | 2019-11-28 | Lizheng Shi | Diabetes risk engine and methods thereof for predicting diabetes progression and mortality |
| EP3686897A1 (en) * | 2019-01-23 | 2020-07-29 | Siemens Healthcare GmbH | Method and data processing unit for selecting a risk assessment computer program |
| US20210311070A1 (en) * | 2018-07-11 | 2021-10-07 | Provigate Inc. | Healthcare management method |
| CN115831364A (en) * | 2022-12-14 | 2023-03-21 | 东北林业大学 | Type 2 diabetes risk layered prediction method based on multi-modal feature fusion |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12236490B2 (en) * | 2023-05-03 | 2025-02-25 | Unitedhealth Group Incorporated | Systems and methods for medical fraud detection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9996889B2 (en) * | 2012-10-01 | 2018-06-12 | International Business Machines Corporation | Identifying group and individual-level risk factors via risk-driven patient stratification |
-
2015
- 2015-11-16 US US14/942,592 patent/US20160357934A1/en not_active Abandoned
-
2022
- 2022-10-10 US US17/962,732 patent/US20230035564A1/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190259104A1 (en) * | 2018-02-16 | 2019-08-22 | Munich Reinsurance America, Inc. | Computer-implemented methods, computer-readable media, and systems for identifying causes of loss |
| US12100056B2 (en) | 2018-02-16 | 2024-09-24 | Munich Reinsurance America, Inc. | Computer-implemented methods, computer-readable media, and systems for identifying causes of loss |
| US20190357853A1 (en) * | 2018-05-24 | 2019-11-28 | Lizheng Shi | Diabetes risk engine and methods thereof for predicting diabetes progression and mortality |
| US20210311070A1 (en) * | 2018-07-11 | 2021-10-07 | Provigate Inc. | Healthcare management method |
| EP3686897A1 (en) * | 2019-01-23 | 2020-07-29 | Siemens Healthcare GmbH | Method and data processing unit for selecting a risk assessment computer program |
| CN115831364A (en) * | 2022-12-14 | 2023-03-21 | 东北林业大学 | Type 2 diabetes risk layered prediction method based on multi-modal feature fusion |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230035564A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230035564A1 (en) | Diabetes onset and progression prediction using a computerized model | |
| US11600390B2 (en) | Machine learning clinical decision support system for risk categorization | |
| Ravaut et al. | Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data | |
| VanSuch et al. | Effect of discharge instructions on readmission of hospitalised patients with heart failure: do all of the Joint Commission on Accreditation of Healthcare Organizations heart failure core measures reflect better care? | |
| US20170308981A1 (en) | Patient condition identification and treatment | |
| DuBrava et al. | Using random forest models to identify correlates of a diabetic peripheral neuropathy diagnosis from electronic health record data | |
| Chen et al. | Excess medical costs in patients with asthma and the role of comorbidity | |
| US20160357923A1 (en) | Dialysis predictive model | |
| US20180181719A1 (en) | Virtual healthcare personal assistant | |
| Hossain et al. | Formulation of a Multi-Disease Comorbidity Prediction Framework: A Data-Driven Case Analysis on of Diabetes, Hypertension, and Cardiovascular Risk Trajectories | |
| US20160371453A1 (en) | Analytical data processing for consumer health scores | |
| US20160358282A1 (en) | Computerized system and method for reducing hospital readmissions | |
| Talukder et al. | Toward reliable diabetes prediction: Innovations in data engineering and machine learning applications | |
| US20250037877A1 (en) | Predicting onset and progression of neurodegenerative diseases using blood test data and machine learning models | |
| Mitravinda et al. | Mental health in tech: Analysis of workplace risk factors and impact of covid-19 | |
| US20240087705A1 (en) | Predictive dosage system and method for behavioral health treatments | |
| Saputra et al. | Hyperparameter optimization for cardiovascular disease data-driven prognostic system | |
| US12475995B2 (en) | Decision support systems for determining conformity with medical care quality standards | |
| Minges et al. | Development and validation of a simple risk score to predict 30‐day readmission after percutaneous coronary intervention in a cohort of medicare patients | |
| Edavally et al. | Artificial intelligence to aid detection and diagnostic accuracy of mood disorders and predict suicide risk: A systematic review | |
| Baser et al. | Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery | |
| KR20220135740A (en) | Psychiatric scale test normalization system | |
| Sun et al. | Patterns of physical and mental co-occurring developmental health among Chinese elderly: A multidimensional growth mixture model analysis | |
| Abas et al. | Machine learning based predictive model of Type 2 diabetes complications using Malaysian National Diabetes Registry: A study protocol | |
| Okolie et al. | Machine learning approaches for predicting 30-day hospital readmissions: Evidence from Massachusetts healthcare data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: HUMANA INC., KENTUCKY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAN, JING;CHIGULURI, VINAY;GOPAL, VIPIN;AND OTHERS;SIGNING DATES FROM 20151116 TO 20151120;REEL/FRAME:037202/0970 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
| STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
| STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
| STCV | Information on status: appeal procedure |
Free format text: BOARD OF APPEALS DECISION RENDERED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |